ASCO Gastrointestinal Cancers Symposium

Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC

January 26th 2025, 7:00pm

Article

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.

The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC

January 26th 2025, 3:00pm

Video

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.

Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer

January 25th 2025, 8:30pm

Article

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.

ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer

January 25th 2025, 7:58pm

Article

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.

Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs

January 25th 2025, 7:36pm

Video

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.

CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer

January 25th 2025, 5:43pm

Article

Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.

Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC

January 25th 2025, 4:00pm

Article

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer

January 25th 2025, 3:02pm

Article

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.

Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract

January 24th 2025, 8:39pm

Article

A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.

Bezuclastinib Plus Sutent May Be Safe and Effective in GIST

January 24th 2025, 6:30pm

Article

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.